ZA201306542B - 7-azaindole derivatives - Google Patents

7-azaindole derivatives

Info

Publication number
ZA201306542B
ZA201306542B ZA2013/06542A ZA201306542A ZA201306542B ZA 201306542 B ZA201306542 B ZA 201306542B ZA 2013/06542 A ZA2013/06542 A ZA 2013/06542A ZA 201306542 A ZA201306542 A ZA 201306542A ZA 201306542 B ZA201306542 B ZA 201306542B
Authority
ZA
South Africa
Prior art keywords
azaindole derivatives
azaindole
derivatives
Prior art date
Application number
ZA2013/06542A
Other languages
English (en)
Inventor
Dieter Dorsch
Thomas Jj Mueller
Gnuni Karapetyan
Christian Sirrenberg
Eugen Merkul
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA201306542B publication Critical patent/ZA201306542B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2013/06542A 2011-02-01 2013-08-30 7-azaindole derivatives ZA201306542B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011009961A DE102011009961A1 (de) 2011-02-01 2011-02-01 7-Azaindolderivate
PCT/EP2012/000067 WO2012104007A2 (de) 2011-02-01 2012-01-09 7-azaindolderivate

Publications (1)

Publication Number Publication Date
ZA201306542B true ZA201306542B (en) 2014-05-28

Family

ID=45554609

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06542A ZA201306542B (en) 2011-02-01 2013-08-30 7-azaindole derivatives

Country Status (18)

Country Link
US (3) US8981101B2 (enExample)
EP (3) EP2670748B1 (enExample)
JP (1) JP5891249B2 (enExample)
KR (1) KR20140014158A (enExample)
CN (3) CN103502247B (enExample)
AR (1) AR085110A1 (enExample)
AU (1) AU2012213775B2 (enExample)
BR (1) BR112013019028A2 (enExample)
CA (2) CA2826051C (enExample)
DE (1) DE102011009961A1 (enExample)
EA (1) EA201300873A1 (enExample)
ES (3) ES2634643T3 (enExample)
HK (1) HK1226394A1 (enExample)
IL (1) IL227689A0 (enExample)
MX (1) MX2013008212A (enExample)
SG (1) SG192133A1 (enExample)
WO (1) WO2012104007A2 (enExample)
ZA (1) ZA201306542B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
ES2606638T3 (es) * 2012-02-21 2017-03-24 Merck Patent Gmbh Derivados de furopiridina
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) * 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CA2975271A1 (en) 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Salicylate inhibitors of melk and methods of use
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016287335B2 (en) * 2015-06-29 2020-01-23 Merck Patent Gmbh TBK/IKKepsilon inhibitor compounds and uses thereof
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
JP7131837B2 (ja) * 2017-06-19 2022-09-06 アビスコ セラピューティクス カンパニー リミテッド Csf-1r阻害活性を有するアザアリール誘導体、その製造方法および応用
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3102645A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) * 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
KR20200046680A (ko) * 2018-10-25 2020-05-07 한국과학기술원 Pdk1 저해제를 포함하는 역노화 유도용 조성물
CN121487921A (zh) * 2023-07-14 2026-02-06 拜西欧斯(北京)生物技术有限公司 异喹啉衍生物、包含其的药物组合物以及它们的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000071524A1 (en) 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
AU2004289539C1 (en) * 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
BRPI0608659A2 (pt) 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
JP2007099640A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
NZ592968A (en) * 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
EP2040546A4 (en) 2006-06-22 2009-12-23 Merck & Co Inc tyrosine kinase inhibitor
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
AU2008226844A1 (en) 2007-03-13 2008-09-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
JP2011500806A (ja) 2007-10-25 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
RU2503676C2 (ru) * 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
DE102008025751A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102008038221A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
EP2576549A4 (en) * 2010-05-24 2013-12-18 Univ Rochester Bicyclic Heteroarylkinase Inhibitors and Methods of Use
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate

Also Published As

Publication number Publication date
EP2670748A2 (de) 2013-12-11
ES2608317T3 (es) 2017-04-07
US9266887B2 (en) 2016-02-23
EP2746281B1 (de) 2017-04-26
AU2012213775A1 (en) 2013-09-19
EP3133074A2 (de) 2017-02-22
HK1226394A1 (zh) 2017-09-29
EP2746281A2 (de) 2014-06-25
CA2826051C (en) 2020-08-18
CN105732617A (zh) 2016-07-06
ES2634643T3 (es) 2017-09-28
US8981101B2 (en) 2015-03-17
CN105732617B (zh) 2017-12-01
ES2861048T3 (es) 2021-10-05
JP5891249B2 (ja) 2016-03-22
SG192133A1 (en) 2013-08-30
IL227689A0 (en) 2013-11-25
US20130310391A1 (en) 2013-11-21
US9725446B2 (en) 2017-08-08
EP3133074B1 (de) 2020-12-09
EP3133074A3 (de) 2017-05-17
US20150152104A1 (en) 2015-06-04
AR085110A1 (es) 2013-09-11
AU2012213775B2 (en) 2016-11-10
BR112013019028A2 (pt) 2016-10-04
US20160130269A1 (en) 2016-05-12
DE102011009961A1 (de) 2012-08-02
CN103502247A (zh) 2014-01-08
CA3082435A1 (en) 2012-08-09
CN105712991B (zh) 2017-12-01
JP2014509313A (ja) 2014-04-17
WO2012104007A2 (de) 2012-08-09
CN103502247B (zh) 2016-02-24
EP2670748B1 (de) 2016-09-28
KR20140014158A (ko) 2014-02-05
MX2013008212A (es) 2013-08-26
EP2746281A3 (de) 2014-10-08
AU2012213775A8 (en) 2013-10-24
EA201300873A1 (ru) 2014-02-28
CN105712991A (zh) 2016-06-29
WO2012104007A3 (de) 2013-10-17
CA2826051A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
TWI562993B (en) Pyrazoloquinoline derivatives
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL232570B (en) Bicyclic dihydroisoquinoline-1-one derivatives
ZA201401884B (en) New dihydroquinoline-2-one derivatives
ZA201401577B (en) New bicyclic dihydroquinoline-2-one derivatives
PT2716642T (pt) Composto de imidazopiridina
IL247638B (en) History of heteroaryl piperidine
SG11201401937YA (en) New aryl-quinoline derivatives
GB201111438D0 (en) Formulation
EP2687531A4 (en) TETRAHYDROCARBOLINE DERIVATIVE
EP2740730A4 (en) DIBENZOOXEPINE DERIVATIVE
IL233001A0 (en) New iso-ergoline histories
IL227509A0 (en) History of 2-methoxy-pyridine-4-yl
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201104284D0 (en) Formulation
GB201105785D0 (en) Thermo-Symbiotic-Gaming